Preparation and in vivo efficacy study of pancreatin microparticles as an enzyme replacement therapy for pancreatitis.
Deficiency manifestations because of pancreatic insufficiency are treated by oral administration of pancreatic enzymes. As pancreatic enzymes get denatured in hostile acidic conditions of stomach, this investigation was aimed at formulating multiparticulates of pancreatic enzymes coated with enteric polymers such as eudragit L100, cellulose acetate phthalate, and hydroxyl propyl methyl cellulose phthalate, which will circumvent gastric inactivation in addition to providing optimal mixing with chyme. Pancreatin microspheres were prepared by emulsification phase separation by nonsolvent addition and solvent evaporation techniques. This process was optimized for core : coat ratio (1:0.5), stirrer speed (350-400 rpm), dispersant concentration, and amount of nonsolvent added to precipitate microspheres. Optimized formulations were assessed for % enzyme content, acid resistance, flow properties, particle size, particle morphology (by standard electron microscopy), compatibility of drug and polymer in formulation (by differential scanning calorimetry), in vitro release kinetics, and in vivo efficacy study in pancreatitis-induced animal model. Capsules containing enteric-coated pancreatin microspheres offered adequate protection to enzymes and prevented their denaturation in acidic environment. Developed multiparticulate dosage forms promoted effective mixing, instant and complete in vitro release compared with marketed tablets.
Naikwade
Sonali Raosaheb
SR
C.U. Shah College of Pharmacy, S.N.D.T. Women's University, Santacruz (W), Mumbai, Maharashtra, India.
Meshram
Rupali Namdeo
RN
Bajaj
Amrita Narayan
AN
D000818:Animals; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004058:Diffusion; D004195:Disease Models, Animal; D004339:Drug Compounding / Q000379:methods; D016503:Drug Delivery Systems; D005260:Female; D008297:Male; D008863:Microspheres; D010179:Pancreas / Q000378:metabolism; D010194:Pancreatin / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use*; D019512:Pancreatitis, Alcoholic / Q000139:chemically induced / Q000188:drug therapy*; D010316:Particle Size; D011108:Polymers / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar
D002214:Capsules; D003692:Delayed-Action Preparations; D011108:Polymers; D010194:Pancreatin